fr

EN DE

fr

EN DE

Publications

2108 PUBLICATIONS - effacer la recherche

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

2022

JCI insight

Yao W

Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment.

2022

Scientific reports

Nguekeu-Zebaze L

PARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells.

2022

Cells

De Azevedo J

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.

2022

Oncoimmunology

Barnestein R

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.

2022

American journal of physiology. Cell physiology

Mallard J

Development of skeletal muscle atrophy and intermuscular adipose tissue in early breast cancer patients treated with chemotherapy.

2022

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Brugel M

Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review.

2022

Surgery

Khellaf L

The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases.

2022

Chemico-biological interactions

McCartin C

An N-heterocyclic carbene iridium(III) complex as a potent anti-cancer stem cell therapeutic.

2022

European journal of cancer (Oxford, England : 1990)

Lepage C

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

2022

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Adotévi O

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.